Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.
Moxifloxacin (Avelox) is a recently-developed fluoroquinolone that has a broad spectrum of antimicrobial activity, including typical respiratory pathogens, atypical and intracellular respiratory pathogens, Gram-negative pathogens and many anaerobes. This spectrum of activity makes moxifloxacin particularly suitable for the therapy of community-acquired respiratory tract infections. It also has enhanced activity against specific bacteria, such as Mycobacteria spp. and Legionella. Moxifloxacin has pharmacologic characteristics that support once-daily dosing regimens and dual routes of excretion that require little or no adjustment for renal or hepatic insufficiency. The drug has maintained an excellent safety profile based upon broad global usage, and no adverse events have occurred that were unanticipated. Streptococcus pneumoniae, which are resistant to earlier fluoroquinolones, are less likely to be resistant to moxifloxacin.
Department of Medicine, Danbury Hospital, Danbury, CT 06810, USA.
Juan-Pablo
JP
Caeiro
Paul B
PB
Iannini
D000818:Animals; D001372:Aza Compounds / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D024841:Fluoroquinolones / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines / Q000737:chemistry / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy
D001372:Aza Compounds; D015507:Drugs, Investigational; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin